Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

ImmunoGen's mirvetuximab soravtansine shows positive effect in Phase 1/2 ovarian cancer study; shares up 12% premarket

Published 03/26/2018, 08:44 AM
© Reuters.  ImmunoGen's mirvetuximab soravtansine shows positive effect in Phase 1/2 ovarian cancer study; shares up 12% premarket
MRK
-
IMGN
-
  • ImmunoGen (NASDAQ:IMGN) is up 12% premarket on the heels of its announcement of positive results from a Phase 1/2 clinical trial, FORWARD II, evaluating mirvetuximab soravtansine, combined with Merck (NYSE:MRK)'s Keytruda (pembrolizumab), in patients with platinum-resistant epithelial ovarian cancer. The data are being presented at the Society of Gynecologic Oncology Annual Meeting in New Orleans, LA.
  • In eight heavily pretreated patients with medium/high folate receptor alpha expression levels, the confirmed overall response rate (ORR) was 63% (n=5/8) with median progression-free survival (PFS) of 8.6 months.
  • The company intends to enroll an additional 35 patients in an expansion cohort.
  • Mirvetuximab soravtansine is an antibody-drug conjugate that targets folate receptor alpha.
  • Now read: Biotech Forum Daily Digest For March 19th


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.